Navigation Links
Gel Developed to Treat Male Menopause

A Brit company has developed a gel that it says can treat hypogonadism, also known as male menopause .

Hypogonadism is a condition that causes reduced libido, erectile dysfunction, baldness, weight gain, lethargy, and irritability.

Like women who grow less fertile as they grow older, in men too the same happens, with age causing a decline in the production of testosterone, the hormone associated with male libido and sexual function, as well as muscle mass and strength, and bone density.

According to ProStraken, the Scottish company behind the male menopause gel, 6 to 12 percent of men over 40, as well as 91 percent of men over 80 suffer from the condition, reports the Telegraph.

The colourless gel has been named Tostran, and contains two per cent synthetic testosterone, which is absorbed through the skin when applied to the shoulders, upper arms or abdomen.

The hormone is then released slowly into the bloodstream, and trials have found that normal levels of it are restored in most men in a matter of hours.

However, boffins are warning that while Testosterone replacement therapies (TRTs) can improve libido and erectile dysfunction, some of them also come with side effects, such as acne, skin reaction, headache and hypertension.


'"/>




Page: 1

Related medicine news :

1. Scientists Developed Map For Brain Molecular Communities
2. Scientists Developed Cheap Way To Assess Sleep
3. Diabetic Friendly Egg Developed In India
4. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
5. Cervical Cancer Vaccine To Be Developed In India
6. Anti-Microbial Coating For Use Over Biomedical Devices Developed
7. Cure for Osteoarthritis To Be Developed
8. Mice With Human Thought Processes Could Be Developed In The Future
9. Viagra Pill For Women To Be Developed
10. Male Contraceptive Pill Being Developed By Berlin Pharmaceutical
11. New Fertility Predictor Test Developed
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gel Developed Treat Male Menopause

(Date:5/16/2008)... study being presented at the American Society of ...20), may change treatment practice in about 25 per...s for proposed changes to the way colorectal cance...ional Cancer Institute (NCI) SEER population-based... III clinical trial data, shows that outcomes of p...
(Date:5/16/2008)... fibroids located just beneath the lining of the u...endometrial cavity after uterine artery embolizati...s, according to a new study. , The study includ...MRI examination before and after UAE. The study fo...% migrated to the endometrial cavity after UAE, sa...
(Date:5/16/2008)...Live Web Cast Scheduled for May 19 at 10:15 a.m. E...all/ - Response Biomedical,Corporation (TSX: RBM, ...hief Executive Officer, is scheduled to present at... Conference on Monday May 19th at 10:15 a.m.,EDT.,...lable on the Company,s,Web site at, http://www.res...
(Date:5/16/2008)...elp docs determine who would benefit most from che... May 16 (HealthDay News) -- A panel of 15 genes ma...on-small cell lung cancer will experience a recurr...erapy, a new study shows. , By extension, the ...with less aggressive forms of the cancer who would...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...blished online in the Environmental Science & Tech...ty, says that bacteria present in the soil can con... the US to toxic forms that could prove harmful to... of environmental engineers at the University of C...
...ed this week says the government’s program (1999) ...ancially deprived families// and their children be...ers. The program targets individual families with...ved areas. It provides outreach or home visiting, ...
...nd or a relative learns that she has cancer she is...ough this, than about herself//. Questions as to h...keep life normal for them during her treatment oft... help, suggests Raising an Emotionally Healthy Chi...
...a's health minister, Manto Tshabalala-Msimang, cla...ne’s diet would delay the onset of AIDS//. She d... warned about the ill effects of the anti-retrovir...arked outrage among the AIDS activist and the medi...
Other Medicine News:Health News:Bacteria Can Convert Flame Retardant Into Toxic Form 2Health News:Helping a Family Going Through an Illness 2
(Date:5/15/2008)... /- Patients with breast or,colorecta...can expect,further treatment advances with Avastin...ollowing new data that is being presented at the 4...nnual meeting in Chicago at,the end of May. Around...ich,is the premier event for cancer therapy worldw...
(Date:5/15/2008)...SCO Showed Acceptable Tolerability Profile, ...hy, WOODCLIFF LAKE, N.J., May 15 /- ...n mesylate (E7389) demonstrated activity in a,heav...vanced or metastatic,breast cancer, according to r...The study also suggests that eribulin mesylate has...
(Date:5/15/2008)...nstrated in Blacks, Hispanics/Latinos, People ... PARSIPPANY, N.J., May 15 /- Daiichi ...at the American Society of,Hypertension,s Twenty- ...Orleans demonstrated that the powerful combination...l) safely and effectively helped,patients across s...
(Date:5/15/2008)...y 15 /- Ergonex Pharma today,announce...ion (FDA) has,granted orphan drug designation to T...ypertension (PAH). Terguride is currently being ev...ope., "The FDA,s grant of orphan drug designation...ur development program by offering regulatory,cli...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 2109 1HealthSouth Declares Dividend on 6 5 25 Series A Convertible Perpetual Preferred Stock 2109 2Industry Executives Finding Value in Shift of Scientific Publications 862 1Industry Executives Finding Value in Shift of Scientific Publications 862 2DuPont and Plantic Technologies Announce Starch Based Bio Materials Collaboration 860 1DuPont and Plantic Technologies Announce Starch Based Bio Materials Collaboration 860 2DuPont and Plantic Technologies Announce Starch Based Bio Materials Collaboration 860 3Mylan to Host Investor Day on October 3 2007 858 1
...rofile Reduction of,testosterone concentration was...r Shionogi initiates Phase 2b trial, QUEBEC CITY, ...ntaris Inc. along with its Japanese partner Shiono...s for a Phase 2a trial with,cetrorelix in benign p...pan. Results showed that cetrorelix, the Company,s...
...- Nutra Pharma,Corp. (OTCBB: NPHC), a biotechnolog...tiple Sclerosis has today announced that its,drug ...ification of,acceptance of its paper for publicati...onference issue., The article, entitled "Alpha-Cob...is; a review of the literature leading to its,deve...
Other Medicine Technology:AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 2AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 3AEterna Zentaris Reports Positive Results with Cetrorelix in BPH,for Japanese Phase 2a Trial 4Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 2Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis 3
Features soft, low friction sheath that extends beyond the tip.
Facilitates intubation of tracheal tubes.
Disposable Aluminum Satin Finish E/T Stylette, Pediatric 11 1/2, 25/box.
Solid Copper Malleable with Adjustable Stop 14.75.
Medicine Products: